Piramal Pharma Solutions Inc. Sustainability Profile
Piramal Pharma Solutions Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates across key regions including North America, Europe, and Asia. Founded in 2004, the company has established itself as a leader in contract development and manufacturing, offering a comprehensive range of services from drug discovery to commercial manufacturing. With a focus on providing innovative solutions, Piramal Pharma Solutions is renowned for its expertise in complex formulations and advanced drug delivery systems. The company’s commitment to quality and customer-centric approach has earned it a strong market position, making it a preferred partner for pharmaceutical and biotechnology companies worldwide. Notable achievements include significant collaborations and a robust portfolio of core products that cater to diverse therapeutic areas, underscoring its role as a vital contributor to the global healthcare landscape.
DitchCarbon Score
How does Piramal Pharma Solutions Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Piramal Pharma Solutions Inc.'s score of 58 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Piramal Pharma Solutions Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Piramal Enterprises Limited, which may influence its climate commitments and reporting practices. While there are no documented reduction targets or specific climate pledges from Piramal Pharma Solutions Inc., it is important to note that emissions data and performance metrics may be inherited from its parent company, Piramal Enterprises Limited. This cascading of data occurs at a level 3 relationship, suggesting that any climate initiatives or targets may be aligned with those set by Piramal Enterprises Limited. As of now, Piramal Pharma Solutions Inc. has not publicly committed to specific science-based targets or initiatives under frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). The absence of these commitments highlights a potential area for growth in their sustainability strategy, particularly in the context of increasing industry standards for climate action and transparency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 40,881,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 86,928,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Piramal Pharma Solutions Inc.'s Industry?
How Carbon Intensive is Piramal Pharma Solutions Inc.'s Location?
Piramal Pharma Solutions Inc.'s Scope 3 Categories Breakdown
Piramal Pharma Solutions Inc.'s Scope 3 emissions, which increased by 11% last year and increased by approximately 5% since 2022, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 79% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 38% of Scope 3 emissions.
Top Scope 3 Categories
Piramal Pharma Solutions Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Piramal Pharma Solutions Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Akums Drugs and Pharmaceuticals Limited
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.